Abstract
Background Spinocerebellar ataxias (SCAs) are a group of heterogeneous autosomal dominant disorders. Spinocerebellar ataxia 4 (SCA4), one of the rarest SCAs, is characterized by adult-onset ataxia, polyneuropathy and linked to chromosome 16q22.1, the underlying mutation remains to be discovered.
Methods Three Swedish families affected by undiagnosed SCA went through detailed examinations, neurophysiological tests, neuroimaging studies and genetic testing. Imaging included MRI of the neuroaxis and brain PET. In 3 cases neuropathological assessments were performed. Genetic testing included SR WGS, STR analysis with Expansion Hunter de novo and long read (LR) WGS.
Results Novel features such as dysautonomia, motor neuron affection, and abnormal eye movements, were found. Anticipation was documented as well. Atrophy in the cerebellum, brainstem and spinal cord was found in patients studied with MRI. [18F]FDG-PET demonstrated brain hypometabolism whereas [11C]Flumazenil-PET yielded reduced binding in several brain lobes, insula, thalamus, hypothalamus and cerebellum. Neuropathological assessment revealed moderate to severe loss of Purkinje cells in the cerebellum. In the spinal cord a marked loss of motor neurons in the anterior horns was seen as well as pronounced degeneration of posterior tracts. Intranuclear, mainly neuronal, inclusions positive for p62 and ubiquitin were sparse but widespread in the CNS. This finding prompted assessment for nucleotide expansions. A poly-glycine stretch encoding GGC expansions in the last exon of the zink finger homeobox 3 (ZFHX3) gene was identified segregating with disease, and not found in 1000 controls.
Conclusions SCA4 is a neurodegenerative disease, caused by a novel GGC expansion in ZFHX3, arguably the first polyglycine disorder in humans.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
Region Stockholm
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The Swedish Ethical Review Authority
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
Supplementary material: One document and video files
Financial disclosures None of the authors report disclosures.
Abbreviation
- SCA4
- Spinocerebellar ataxia type 4
The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, University of Washington, and Vrije Universiteit Amsterdam.